Onco Wiki / Indication

Gastric / GEJ adenocarcinoma · line 1 · Bemarituzumab + mFOLFOX6 (FORTITUDE-101) — 1L FGFR2b-overexpressing HER2-non-positive gastric/GEJ

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Ligne thérapeutique1
Voieagressif
Régime liéREG-BEMARITUZUMAB-MFOLFOX6
IDIND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB
TypeIndication
Étatreviewed 2026-05-07 | pending_clinical_signoff
MaladiesDIS-GASTRIC
SourcesSRC-ESMO-GASTRIC-2024 SRC-FORTITUDE-101 SRC-NCCN-GASTRIC-2025

Notes

STUB — pending Clinical Co-Lead sign-off (CHARTER §6.1: ≥2 reviewers for clinical content). Aggressive-track 1L for HER2-negative / MSI-stable / CLDN18.2-negative / FGFR2b-positive metastatic gastric / GEJ. Confidence: MODERATE — FORTITUDE-101 phase 3 primary analysis positive (mOS HR 0.61, p=0.005, ESMO 2025 LBA10) but attenuated at descriptive follow-up (HR 0.82) — practice-changing status disputed. SRC-FORTITUDE-101 upgraded from TODO-stub to canonical ESMO 2025 abstract-tier citation (GI-2 bemfill chunk 2026-05-07-1830); evidence_tier=2 because peer-reviewed full publication not yet indexed (paper_pending). REG-BEMARITUZUMAB-MFOLFOX6 created in same chunk (15 mg/kg IV q2w + mFOLFOX6 backbone). Engine routing to this indication will not fire until algorithm extension adds FGFR2b biomarker requirement (D1 algorithm chunk recommended). UA access: bemarituzumab not registered; named-patient / charitable / clinical-trial pathway only.

Utilisé par

Algorithmes

Sources